Пилотное исследование влияния резвератрола по сравнению с розувастатином и их комбинации на липидный спектр у больных с гипертонической болезнью

Tobacco consumption, hypertension and dyslipidemia are the major risk factors for risk adapted non-communicable diseases, accounting for the highest morbidity and mortality among the Bangladeshi population. The objective of this study was to determine the association between tobacco consumption and changes of serum lipid profiles in hypertensive patients. This cross sectional study was conducted among 308 (202 males and 106 females) hypertensive patients attending in OPD of National Heart Foundation Hospital, Dhaka, Bangladesh between January, 2009 to June, 2009, aged 20 years and older. Among all participants, 46.10% (n = 142) were tobacco smoker, 9.09% (n = 28) were past smoker, 44.80% (n = 138) were never smoked and 28.89% (n = 89) were present smokeless tobacco consumer, 24.35% (n = 7S) were past smokeless tobacco consumer and 46.75% (n = 144) were never consumed smokeless tobacco in their lifetime. Among all the hypertensive participants (n = 308) 28.9% have high total cholesterol (>221 mg%) and 71.1% have normal total cholesterol; 71.4% have low HDL (<36mg %) and 28.6% have normal HDL; 13.3% have high LDL (>151mg %) and 86.7% have normal LDL; 70.1% have high triglycerides (>201mg %) and 29.9% have normal TG. While, the lipid profile of the cigarette smokers (n = 142) group have shown, 29.57% have high total cholesterol and 70.4% have normal total cholesterol; 69.7% have low HDL and 30.3% have normal HDL; 11.3% have high LDL and 88.7% have normal LDL; 78.2% have high TG and 21.8% have normal TG. After computing the Chi-square test it has shown that the tobacco consumption has influence on LDL-cholesterol and TG level which were statistically significant at P-value 0.05. The alteration of lipid profile in smokers has raised serious medical concern with respect to atherogenic risks, ischaemic heart diseases, strokes and other comorbidities. Stringent recommendations regarding counseling the smokers to quit smoking and checking their serum lipid profile at regular intervals should have suggested. Health professionals have the greatest potential of any group in society to promote the reduction of tobacco use. Brief advice from health professionals can increase quitting success rates and intensive advice may increment the chance of quitting tobacco. Key Words: Serum lipid profile, Tobacco consumption, Hypertension, Total Cholesterol (TC), High density lipoprotein (HDL), Low density lipoprotein (LDL), Triglycerides (TG).

Hydroxychloroquine has been suggested to exert lipid lowering effects. The purpose of this study was to determine the effect of hydroxychloroquine on total cholesterol and on other lipoproteins in a controlled trial involving patients with systemic lupus erythematosus (SLE). Seventeen female patients with SLE were enrolled in a double-blind, randomized, placebo-controlled, multiple-dose pilot study comparing placebo with hydroxychloroquine at daily doses of 400 and 800 mg. The primary endpoint was alteration in total cholesterol. Patients were evaluated at two screening visits pretreatment and at three monthly follow-up visits. At all visits, a fasting panel of lipoproteins, disease activity, and adverse drug effects were assessed. There were no significant alterations in lipoproteins in patients receiving placebo. Treatment with 400 mg/day of hydroxychloroquine resulted in a significant decrease in total cholesterol (mean decrease of 11.6 mg/dL). Treatment with 800 mg/day of hydroxychloroquine resulted in a significant decreases in total cholesterol (mean decrease of 13.4 mg/dL), triglycerides, very low density lipoproteins, cholesterol, and the ratios of total cholesterol/high density lipoprotein cholesterol and low density lipoprotein/high density lipoprotein cholesterol. More adverse effects were noted among patients receiving the high dose (800 mg/day). Hydroxychloroquine affects a significant reduction in total cholesterol in patients with SLE. The findings of this double-blind, placebo-controlled, pilot trial support the conclusions of earlier open trials. This lipid-lowering effect may be an added benefit of hydroxychloroquine treatment in these patients with a high prevalence of atherosclerotic cardiovascular disease.

Effect of colestipol and clofibrate on plasma lipid and lipoproteins in Type IIa hyperlipoproteinemia

The objective of this study is to determine the relationships between plasma atorvastatin concentrations, LDL (low-density lipoprotein) cholesterol reduction, and atorvastatin dose; the earliest time at which lipid levels change when atorvastatin treatment is initiated or discontinued; and alterations in LDL particle composition. Twenty-four subjects with elevated LDL-cholesterol were treated with escalating daily doses of 5, 20, and 80 mg atorvastatin for 6 weeks each. Serial plasma lipid and lipoprotein analyses were performed during the initiation and discontinuation of atorvastatin therapy, as well as at steady state. LDL-apolipoprotein B and LDL-cholesterol were measured directly after ultracentrifugation, and LDL-cholesterol also was estimated by the method of Friedewald. Steady-state atorvastatin pharmacokinetic parameters were estimated on the last day of each dosing period. LDL-cholesterol (Friedewald) reductions of 34%, 43%, and 57% were produced by atorvastatin doses of 5, 20, and 80 mg, respectively. The mean dose-response relationship was log linear, and almost all individual dose-response curves paralleled the mean curve. LDL-apolipoprotein B reductions were slightly less than those of LDL-cholesterol. Atorvastatin area under the curve (AUC(0-24) values increased proportionally with dose, while values of Cmax (maximum concentration) increased more than proportionally, and Cmin (minimum concentration) increased less than proportionally. Following initiation of dosing, statistically significant decreases in total cholesterol, LDL-cholesterol (beta quant), and LDL-apolipoprotein B were observed within 24 hours and in LDL-C (Friedewald) within 72 hours. Following discontinuation of drug dosing, statistically significant increases were observed in total cholesterol and LDL-cholesterol (Friedewald) within 48 hours and in LDL-cholesterol (beta quant) and LDL-apolipoprotein B within 72 hours. At each dose, an individual's LDL-cholesterol response was not correlated with AUC(0-24). In conclusion, atorvastatin produces marked LDL-cholesterol reductions, the mean dose-response relationship is log linear, almost all individual dose-response curves parallel the mean dose-response curve, onset and cessation of action are rapid, the estimated and measured LDL-cholesterol are the same, LDL-cholesterol and LDL-Apo B reductions are similar, and plasma concentrations are not correlated with LDL-cholesterol reduction at a given dose.

Obesity is a worldwide epidemic and there are many diseases associated with it. Recent studies suggested that melatonin may be involved in the regulation of body mass and metabolic homeostasis through different mechanisms.To this purpose, we conducted an experimental study on 24 adults male Wistar rats, separated into 2 control groups and 1 test group. Our experimental protocol took place in three phases, an obesity induction phase in which the rats were subjected to a hyper fat diet “Cafeteria diet”. A therapeutic phase in which the control group received NaCl as a placebo, the test group was treated with melatonin at a dose of 5mg/kg/day. The groups were randomized and received treatment intraperitoneally for 6 weeks. A Biological blinded evaluation for lipidic, glucidic, and inflammatory (CRP) assessments were performed for each group.The results of our study showed that the Cafeteria diet significantly increased body weight with a gain of up to 126g (p=0.00). The biological analysis of the blood of rats treated with melatonin showed a decrease in blood glucose levels, triglycerides, LDL, HDL, CRP and total cholesterol compared to the initial values. Plasma analysis results obtained at the end of the therapeutic phase between melatonin and placebo‐treated rats showed a significant decrease in total cholesterol (p=0.002), LDL (p=0.005), HDL (p=0.014) and blood glucose (p=0.013). The difference between the two groups for CRP (p=0.084) and triglycerides (p=0.116) was not significant.Based on our results melatonin seems to have a beneficial effect against metabolic disorders related to obesity.Support or Funding InformationN/A

Introduction: Hypertension is a leading cause of mortality and morbidity worldwide. It doubles the risk of cardiovascular diseases. Elevated serum lipoprotein (a) are associated with an increasing risk of cardiovascular disease in hypertensive patients. Aims and Objectives: To determine levels of serum lipoprotein (a) and lipid profile in hypertensive patients and to correlate the serum lipoprotein (a) levels with lipid parameters. Material and Methods: Lipid profile and serum lipoprotein (a) were estimated in 68 hypertensive patients and compared with 63 age and sex matched healthy controls. Serum lipoprotein (a) was estimated by immunoturbidometric assay and lipid profile by standard biochemical methods. Result: Serum lipoprotein (a) was found to be significantly increased (p<0.001) in hypertensive patients (36.52 ± 9.34 mg/dl) as compared to healthy individuals (17.96 ± 8.42 mg/dl). Total cholesterol, LDL, triglycerides were significantly increased (p<0.001) and HDL was significantly decreased (p<0.001) in cases compared to controls. The correlation study between serum lipoprotein (a) and lipid profile in hypertensive cases showed, that only LDLc had a significant positive correlation with lipoprotein (a). Conclusion: Elevated lipoprotein (a) in hypertensive patients can be a independent risk factor for development of cardiovascular disease.

Background: Western New York is among the regions with the highest rate of heart disease and stroke in the United States. Multifactorial causes include hypertriglyceridemia and dyslipidemia, and additional therapies may be needed to reduce residual risk that remains even after treatment with statins or other lipid-lowering medications. The purpose of this study was to evaluate the effects of a switch from omega-3 fatty acid ethyl esters (OM3EE) to icosapent ethyl (IPE) on lipid profiles in patients with hyperlipidemia. Methods: This was a retrospective chart review of patient records extracted from multiple medical practices throughout Western New York (4 locations). Randomly selected patients (N = 15) were eligible if they were aged ≥ 18 years with diagnosis codes for high triglyceride (TG) levels or hyperlipidemia and were receiving OM3EE. They were switched from OM3EE to IPE, and lipid parameters were measured after ≥ 2 months. Results: The records of 15 patients were analyzed and lipid measurements were available for 14 patients; 10 were on statins and 4 were on ezetimibe. At ≥ 2 months after the switch to IPE, 13 patients experienced decreases in total cholesterol (TC) and non–high-density lipoprotein cholesterol (non–HDL-C) levels; 12 experienced a decrease in TG and low-density lipoprotein cholesterol (LDL-C) levels; and changes in HDL-C levels were varied, with no change in 1 patient, decreases in 9 patients, and increases in 4 patients. Conclusion: The results of this real-world retrospective analysis of 14 patients with hyperlipidemia demonstrated reductions in TG, LDL-C, TC, and non–HDL-C levels, with mixed results in HDL-C levels, after switching from OM3EE to IPE.

vegetarian diets have been associated with lower risk of cardiovascular disease and a more favourable lipid profile in vegetarians who follow these diets for a long term period in observational studies, but the short-term effects of vegetarian diets are less known. our objective was to analyze the short-term effects of a low-fat vegetarian diet on lipid profile and fasting glucose in previously non-vegetarian subjects from a Mediterranean population. we carried out a nutritional intervention study in 159 volunteers (42 men and 117 women). A whole lacto-vegetarian diet low in fat (20%) was administered. A full daily menu was provided for 15 days under strict interned conditions. Fasting blood samples were obtained before and after dietary intervention and total cholesterol, HDL-C, LDL-C, triglycerides and fasting glucose were determined. Multivariate models for repeated measures were used. after dietary intervention, we detected statistically significant reductions in total cholesterol (-17.54 ± 37.14 mg/dl), LDL-C (-9.33 ± 34.29 mg/dl), HDL-C (-5.32 ± 12.16 mg/dl), and triglycerides (-18.92 ± 50.50 mg/dl). These reductions remained statistically significant after adjustment for sex and age. Significant weight changes were also detected. The additional adjustment for changes in body mass index (BMI) attenued the significance of the decrease in triglycerides (P = 0.067). a lacto-vegetarian diet low in fat, produces favourable and significant decreases in total cholesterol, LDL-C (independent of weight loss) and triglycerides (mediated by weight loss). This intervention also produced an expected decrease in HDL-C due to its reduced fat content.

BackgroundPsoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles.MethodsWe compared changes in lipid profiles in a population based incident cohort of 689 patients with psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles.ResultsThere were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the 5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort. Triglyceride (TG) levels were significantly higher (p<0.001), and HDL levels significantly lower (p=0.013) in patients with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering drugs between the two cohorts.ConclusionsPatients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further exploration.

Outcome After Steroid Withdrawal in Heart Transplantation

This systematic review aimed to gather data on the effects of sumac supplementation on lipid profile. A systematic literature search was carried out using electronic databases (PubMed, Scopus, and Web of Science) up to March 2023 to identify eligible randomized controlled trials (RCTs) assessing the effects of sumac intake on lipid profile as an outcome. All participants enrolled in our study were adult individuals who consumed sumac, in various forms, as an intervention. The included articles were assessed using the Cochrane risk of bias assessment tool. Heterogeneity tests of the selected trials were performed using the I2 statistic. Random effects models were assessed based on the heterogeneity tests, and pooled data were determined as the weighted mean difference with a 95% confidence interval. In total, seven RCTs with a total sample size of 570 subjects were included. This study found a significant decrease in total cholesterol (TC) (weighted mean difference [WMD]: -10.01 mg/dL; 95% CI: -18.67, -1.34), triglyceride (TG) (WMD: -8.52 mg/dL; 95% CI: -14.79, -2.25), and low-density lipoprotein (LDL)-C levels (WMD: -9.25 mg/dL; 95% CI: -14.56, -3.93); Moreover, a significant increase was observed in high-density lipoprotein (HDL)-C concentration (WMD: 2.97 mg/dL; 95% CI: 0.75, 5.19). The reduction in TG and TC was greater in studies with a duration of ≥12 compared to <12 weeks. The increase in HDL-C was greater in participants with an intervention duration of ≥12 compared to <12 weeks. Moreover, subgroup analysis based on the dose of sumac suggested a significant reduction in TC and LDL, specifically for doses below 3 g. Consumption of sumac significantly decreased serum TC, LDL-C, and TG concentrations. This study suggested significantly positive effects on HDL-C by intake of sumac. Longer interventions (>12 weeks) have a more favorable impact on TC, LDL-C, and HDL-C, while sumac doses below 3 g/day show greater effects on TC and LDL-C. These findings underscore the potential of sumac supplementation as a valuable approach to lipid profile management.

Background: Dyslipidaemia and hypertension are the commonest risk factors for coronary artery disease (CAD). To study the lipid profile in hypertensive patients.&#x0D; Methods: The present study was carried out on a total of 100 hypertensive patients attending our Hospital and 100 age and sex matched healthy controls. Twelve hour fasting lipid analysis was done for Serum triglycerides (TG), total cholesterol(TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL).&#x0D; Results: The Mean serum total cholesterol values were highly significant in hypertensive subjects (235.36±32.36mg/dL) as compared to the healthy control subjects (152.36±12.01mg/dL). The mean serum TG level was 110.36±16.12 mg/dl in healthy control subjects, and 215.23±35.36 mg/dl in hypertensive patients. This difference was highly significant. The mean values for HDL was 27.23±6.02 mg/dL for hypertensive subjects whereas 43.21±5.36 mg/dl for healthy control subjects, respectively. The Mean serum LDL values were highly significant in hypertensive subjects (154.36±31.26 mg/dL) as compared to the healthy control subjects (95.36±16.02mg/dL).&#x0D; Conclusion: All the lipid profile like cholesterol, LDL, TG and HDL were derange in the hypertensive than those in the healthy controls.&#x0D; Keywords: Hypertension ,Lipid profile, HDL ,TG , LDL.

Background: Changes in lipid profile have long been associated with malignancies as lipids play a key role in maintenance of cell integrity. This study evaluated the alterations in extended lipid profile in untreated patients of oral submucous fibrosis (OSMF) and studied the correlation between lipid levels with tobacco consumption. Materials and methods: In this hospital-based study, 65 clinically diagnosed and histopathologically proven patients of OSMF and 42 age and sex matched controls were studied. In these samples serum lipids including: (i) Total cholesterol, (ii) LDL cholesterol (LDLC), (iii) HDL cholesterol (HDLC) (iv) VLDL cholesterol (VLDLC) (v) triglycerides (vi) Apo-A1 (viii) Apo-B and (viii) LPa were analyzed. Results: A significant decrease in plasma total cholesterol, HDLC and Apo-A1 was observed in patients with OSMF as compared to the controls. Thus an inverse relationship between plasma lipid levels and patients was found in OSMF. Conclusion: The lower levels of plasma cholesterol and other lipid constituents in patients might be due to their increased utilization. The findings strongly warrant an in-depth study of alterations in plasma lipid profile in patients with oral precancerous conditions.

Objective: This study was conducted to investigate the relationship between serum lipid profile and breast cancer disease.Patients and methods: One hundred breast cancer women and 75 women with benign breast mass as a control group were included in the study. The control and the patient groups were aged matched. The age range of the control group was between 25 to 70 years (mean ± SD: 50.4 ± 15.1 years). The age range of the patient group was between 25 to 71 yeas (mean ± SD: 49.1 ± 14.6 years). The patients were undergone radical modified mastectomy, then treated with chemotherapy and radiotherapy after the operation. Five mL of blood samples from the patient and control groups were taken, and the patient samples were taken before the operation. The blood samples were analyzed for serum lipid profile. The patients and the control groups were advised to fast for 14 hours before taking the blood samples. Body mass index was measured for the patients and controls. The stage, lymph involvement, and metastasis of the cancer were also included.Results: Body mass index (BMI) in patients was significantly higher than controls. However, serum total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C) and atherogenic index (AI), in the patients were significantly lower than controls. High-density lipoprotein cholesterol (HLD-C) was higher in the patients compared with the controls but not significant.Conclusion: a significant decrease in TC, TGs, and LDL-C with no significant increase for HDL-C was noticed in breast cancer women. Serum lipid profile may not be considered as a risk factor for breast cancer.

Oxidative stress is one of the main mechanisms associated with the pathogenesis of amyotrophic lateral sclerosis (ALS). Copper can affect cellular oxidation and lipid metabolism. The aim of this study was to evaluate the association of copper status with lipid profile and functional status in patients with ALS. A cross-sectional study was carried out including 27 patients with ALS (case group) and 26 healthy individuals (control group). Copper status was evaluated by habitual dietary copper intake, plasma copper, and serum ceruloplasmin concentrations. The lipid profile included analysis of serum total cholesterol (TC), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), and triglycerides (TGL). The functional status of patients with ALS was assessed by the ALS Functional Rating Scale-Revised (ALSFRS-R). In the case group, plasma copper was lower compared with the control group (133.9 versus 164.1 μg/dL, p=0.0001) and was positively correlated with HDL-c (rs=0.398, p=0.044). In the control group, plasma copper was positively correlated with serum ceruloplasmin (rs=0.646, p < 0.001), TC (rs=0.446, p=0.025), LDL-c (rs=0.445, p=0.029), and HDL-c (rs=0.479, p=0.015), and serum ceruloplasmin was positively correlated only with LDL-c (rs=0.407, p=0.043). In the case group, dietary copper intake (B=−0.373, p < 0.001), plasma copper (B=−0.005, p=0.033), and TC (B=−0.312, p=0.001) were inversely associated with the functional status of patients with ALS. In contrast, serum ceruloplasmin (B=0.016, p=0.044), LDL-c (B=0.314, p=0.001), HDL-c (B=0.308, p=0.001), and TGL (B=0.062; p=0.001) were positively associated with their functional status. In conclusion, this study suggests a disturbance of copper status and its connection with the lipid profile in patients with ALS. Furthermore, copper status and lipid profile may influence the functional status of patients with ALS, standing out as potential biomarkers of disease severity.